Macrogenics reported $67.82M in Operating Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 11288M 2467M
Amgen AMGN:US $ 4.42B 680M
AstraZeneca AZN:LN 10.23B 280M
Biogen BIIB:US $ 2648.2M 727.1M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Cerulean Pharma CERU:US $ 8.4M 1.14M
Daiichi Sankyo 4568:JP 245.94B 38.74B
Eli Lilly And LLY:US $ 5277.9M 127.8M
Epizyme EPZM:US $ 57.33M 2.29M
Genmab GEN:DC 1.92B 310M
Geron GERN:US $ 28.05M 749K
Gilead Sciences GILD:US $ 4231M 2162M
Immunogen IMGN:US $ 75.22M 14.28M
Johnson & Johnson JNJ:US $ 18.18B 616M
Karyopharm Therapeutics KPTI:US $ 82.59M 331K
Macrogenics MGNX:US $ 67.82M 9.92M
Merk MRK:US $ 9666M 666M
Mirati Therapeutics MRTX:US $ 182.57M 2.36M
Pfizer PFE:US $ 15640M 148M
Puma Biotechnology PBYI:US $ 47.52M 1.01M
Regeneron Pharmaceuticals REGN:US $ 1747.3M 40.7M
Seattle Genetics SGEN:US $ 630.61M 71.1M
Xencor XNCR:US $ 58.18M 854K